Biolinerx LTD. 6-K Filing
Ticker: BLRX · Form: 6-K · Filed: Nov 17, 2025 · CIK: 1498403
Sentiment: neutral
Filing Stats: 195 words · 1 min read · ~1 pages · Grade level 10.6 · Accepted 2025-11-17 07:12:44
Filing Documents
- zk2534026.htm (6-K) — 11KB
- exhibit_99-1.htm (EX-99.1) — 15KB
- image0.jpg (GRAPHIC) — 27KB
- 0001178913-25-003874.txt ( ) — 65KB
From the Filing
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2025 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant's name into English) 2 HaMa'ayan Street Modi'in 7177871, Israel (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F Form 40-F CONTENTS Attached hereto and incorporated herein is the registrant's press release issued on November 17, 2025, titled "BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types." EXHIBIT INDEX Exhibit No. 99.1 Press release titled: "BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types." Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioLineRx Ltd. By: /s/ Philip A. Serlin Philip A. Serlin Chief Executive Officer Dated: November 17, 2025